Rosmarin, David
Soliman, Ahmed M.
Marwaha, Simran
Piercy, James
Camp, Heidi S.
Anderson, Peter
Ezzedine, Khaled
Funding for this research was provided by:
AbbVie
Article History
Received: 1 April 2024
Accepted: 10 June 2024
First Online: 26 June 2024
Declarations
:
: David Rosmarin has consulted, spoken for, or conducted trials for AbbVie, Abcuro, AltruBio, Amgen, Arena, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio. Ahmed M. Soliman and Heidi S. Camp are full-time employees of AbbVie and may hold AbbVie stock and/or stock options or patents. Khaled Ezzedine declares acting as a consultant for Incyte, La Roche Posay, Pfizer, Pierre Fabre, Almirall, MSD, BMS, and AbbVie. Simran Marwaha, James Piercy, and Peter Anderson are employees of Adelphi Real World.
: This analysis was conducted on existing de-identified data; therefore, the study team did not have access to any personal information on the patients or physicians and as such this study did not require ethics committee approval. As part of the DSP, patients were asked to complete a declaration page where they agreed to partake in the completion of the patient self-completion form in accordance with HIPAA and equivalent European Union guidelines. The DSP was submitted to the Pearl institutional review board. National data collection regulations were adhered to (European Society for Opinion and Market Research; US Department of Health and Human Services National Institutes of Health HIPAA; The Market Research Society; British Standards Institute).